Skip to content
Menu
About Us
Overview
Management Team
Board of Directors
Contact Us
Royalty Portfolio
Opportunities
Overview
Royalty Acquisition
Assets Available for Licensing
Phage Display Platform
Ebopiprant
Anti-prolactin Antibody
XMetA Portfolio
News
Company & Partner News
Press Releases
Investors
Overview
News & Events
Financial Information
Stock Data
Analyst Coverage
SEC Filings
Governance
Contact
Menu
About Us
Overview
Management Team
Board of Directors
Contact Us
Royalty Portfolio
Opportunities
Overview
Royalty Acquisition
Assets Available for Licensing
Phage Display Platform
Ebopiprant
Anti-prolactin Antibody
XMetA Portfolio
News
Company & Partner News
Press Releases
Investors
Overview
News & Events
Financial Information
Stock Data
Analyst Coverage
SEC Filings
Governance
Contact
Clinical Trials
RZ358
An Open-Label Multiple Dose Study of RZ358 in Patients With Congenital Hyperinsulinism
RZ358 Treatment for Congenital Hyperinsulinism